OBJECTIVES: Prior research has focused on the relationship between weight change and incidence of metabolic syndrome. Change in body mass index (BMI), components of metabolic syndrome and metabolic syndrome status were investigated over 1 year of follow-up. METHODS: Subjects with metabolic syndrome from a community health screening project were recruited. Logistic regression was used to analyse the disappearance or remission of metabolic syndrome during 1 year according to changes in BMI, waist circumference, triglycerides, blood pressure, high-density lipoprotein-cholesterol (HDL-C) and fasting plasma glucose (FPG). RESULTS:
Introduction
In 1993, Reaven proposed the term "Syndrome X" to describe insulin resistance syndrome, which is now known as metabolic syndrome. 1 Metabolic syndrome was found to increase the risk of cardiovascular disease, type 2 diabetes mellitus and all-cause mortality. 2,3 Most research on the risk factors associated with metabolic syndrome has involved cross-sectional surveys. 4 Some research has reported on the incidence of metabolic syndrome in Asia; 5 -7 however, there have been no reports on the disappearance of metabolic syndrome without intervention in Asian people. Some studies have investigated weight change and the incidence of metabolic syndrome, 5 but there has been little focus on the relationship between five components of metabolic syndrome (namely, fasting plasma glucose [FPG] , waist circumference, blood pressure, triglyceride levels, high-density lipoproteincholesterol [HDL-C] levels), body mass index (BMI) and the incidence of metabolic syndrome. The present study investigated whether short-term fluctuations in any of these components were associated with the disappearance of metabolic syndrome without intervention.
Subjects and methods

STUDY POPULATION
This retrospective study analysed data from the Li-Shin Outreach Neighbourhood Screening (LIONS) programme, the design of which has been described previously. 8 The LIONS programme recruited citizens of Pingzhen City, Taiwan, who were aged > 30 years. Residents went through multiple health screening, undertaken by an outreach community service, once a year from 2002 onwards. During the study period (2002 -2008) , data on disease and health status were collected annually for each consecutively enrolled subject. Target  diseases of the screening programme  included  three  chronic  conditions  (hyperlipidaemia,  hypertension and diabetes mellitus) and five cancers (liver, breast, oral, cervical and colon cancer).
The project was conducted at the Taiwan Landseed Hospital, Pingzhen City, Taiwan. Eligible subjects had to have 2 years of consecutive data between 2002 and 2008, and metabolic syndrome, according to the diagnostic criteria described below, in their first year in the study. Subjects who were pregnant, lost to follow-up during the second year and those with missing data on any of the risk factors associated with metabolic syndrome (including sex, age, height, weight, smoking status, alcohol consumption, betel nut consumption, waist circumference, systolic or diastolic blood pressure [SBP/DBP], triglycerides, HDL-C, FPG) and receiving medication to treat hypertension, diabetes and hyperlipidaemia were excluded from the study.
The study protocol was approved by the Institutional Review Board of the Taiwan Landseed Hospital (IRB-10-07). Written informed consent was obtained from all participants.
DIAGNOSIS OF METABOLIC SYNDROME
Metabolic syndrome was defined according to Taiwan Department of Health criteria, using the modified American Heart Association/National Cholesterol Education Program Adult Treatment Panel III (AHA/NECP ATP III) definition based on Asian waist circumference. 9,10 Metabolic syndrome was diagnosed in patients who met three or more of the following criteria: 1, central obesity (waist circumference ≥ 90 cm for men and ≥ 80 cm for women); 2, elevated triglycerides (≥ 150 mg/dl); 3, decreased H-C Chang, J-T Horng, T-T Chau et al.
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HDL-C (< 40 mg/dl for men and < 50 mg/dl for women); 4, elevated blood pressure (SBP ≥ 130 mmHg or DBP ≥ 85 mmHg) or normal blood pressure controlled with antihypertensive therapy; 5, elevated FPG (FPG ≥ 100 mg/dl) or normal FPG controlled with diabetes medication.
Subjects were categorized as 'yes', 'quit', or 'no' according to smoking status, betel nut and alcohol consumption.
ONE-YEAR ANALYSIS OF METABOLIC SYNDROME
The five components of metabolic syndrome and BMI were analysed during a 1-year period by comparing data taken over 2 years; each component of metabolic syndrome and BMI was measured once in year 1 and once in year 2 for each patient. The disappearance of metabolic syndrome was defined as absence of three or more of the five components described above. The differences between the values of the first and second year in each of the five components and BMI were calculated: difference in component value (except HDL-C) = first-year minus second-year value; difference in HDL-C value = second-year minus first-year value. Data were divided into quartiles based on a nearly equal number of subjects, and the quartile containing patients with no/little difference was set as the reference group for comparison of each component of metabolic syndrome and BMI.
STATISTICAL ANALYSES
All analyses were performed using SPSS ® software, version 14.0 (SPSS Inc., Chicago, IL, USA). Study variables were analysed using the appropriate statistical methods, including Student's t-test and the χ 2 -test. Logistic regression modelling was used to analyse the relationship between the change in each component of metabolic syndrome and BMI, in subjects considered to be in remission or with disappearance of metabolic syndrome after 1 year. For each demographic and clinical characteristic, crude odds ratios and adjusted odds ratios according to two models were calculated: model 1, lipid-lowering medication use as neither criterion for triglycerides nor for HDL-C; model 2, lipid-lowering medication use as positive criterion for both triglycerides and for HDL-C. A P-value ≤ 0.05 was considered to be statistically significant.
Results
A total of 490 subjects (males n = 251; females n = 239) with metabolic syndrome, with a mean ± SD age of 58 ± 12 years, was included in the study. The rate of disappearance of metabolic syndrome at 1 year was 30% (147/490). Comparison of clinical characteristics of subjects with metabolic syndrome in year 1, and with and without metabolic syndrome after 1 year of follow-up, are shown in Table 1 .
The differences between the value of the first year and the second year of the five components and BMI were divided into quartiles (Table 2) After adjusting for sex, age and baseline BMI in logistic regression model 1, a decrease in SBP of ≥ 14 mmHg, an increase in HDL-C of ≥ 5 mg/dl, a reduction in triglycerides of ≥ 67 mg/dl and a reduction in DBP of 3 -9 mmHg significantly increased the likelihood of metabolic syndrome disappearing in 1 year. Waist circumference, FPG levels and BMI were not associated with the disappearance of metabolic syndrome.
If the use of lipid-lowering medicine was included as a positive criterion for both triglycerides and HDL-C (model 2), the multivariate logistic regression analysis for the 1-year disappearance of metabolic syndrome revealed no obvious difference compared with model 1 (Table 2) . Atherosclerosis Society proposed a joint definition of metabolic syndrome 15 as including any three of the following five components: elevated waist circumference according to population-and country-specific definitions; elevated triglycerides (drug treatment as an alternate indicator) ≥ 150 mg/dl; reduced HDL-C (drug treatment as an alternate indicator) < 40 mg/dl in males, < 50 mg/dl in females; elevated blood pressure (drug treatment as an alternate indicator) of systolic ≥ 130 and/or diastolic ≥ 85 mmHg; elevated FPG (drug treatment as an alternate indicator) ≥ 100 mg/dl.
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In Asia, the prevalence of metabolic syndrome is high, affecting 18% of the population in the Philippines, 16 25 -27% in South Korea, 17 15 -23% in Singapore, 18 15 -27% in China 19 -21 and 10 -27% in Taiwan. 22 -24 Few studies have investigated the incidence of the metabolic syndrome in Asia. 4 Based on the NCEP ATP III definition, the 3-year incidence in Iran 5 and South Korea 6 has been assessed; using the Asian criteria for abdominal obesity ATP III, the 10year incidence 7 and 4-year incidence in Taiwan 25 has been reported. No study, however, has investigated the remission or disappearance of metabolic syndrome without intervention in Asian populations.
Some studies have investigated the relationship between weight change and incidence of metabolic syndrome, 5,6 but there has been no focus on the relationship between changes in the five components assessed in the present study and the incidence of metabolic syndrome. To our knowledge, this is the first study to explore the association between short-term fluctuations in the five components of metabolic syndrome and the disappearance of metabolic syndrome without intervention. 
TABLE 1 (continued): Comparison of characteristics among 490 subjects who had metabolic syndrome in the first year of a screening study, stratified by cases with and without metabolic syndrome after 1 year of follow-up
H-C Chang, J-T Horng, T-T Chau et al. Disappearance of metabolic syndrome after 1 year TABLE 2: Logistic regression analysis of the relationship between changes in five components and body mass index (BMI) and the disappearance of metabolic syndrome, divided by quartiles, in 490 subjects with metabolic syndrome in the first year of study
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Metabolic syndrome disappeared after 1 year in approximately one third of subjects in the present study; this disappearance was not related to the treatment of metabolic syndrome in these subjects. As metabolic syndrome was not a target disease for screening in the LIONS programme, no prospective diagnosis of metabolic syndrome was made in the health screening report for any subject. This study analysed the disappearance of metabolic syndrome retrospectively, and was not therefore related to the management of metabolic syndrome. The only treatments administered to study 
TABLE 2 (continued): Logistic regression analysis of the relationship between changes in five components and body mass index (BMI) and the disappearance of metabolic syndrome, divided by quartiles, in 490 subjects with metabolic syndrome in the first year of study
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subjects that may have impacted on the metabolic syndrome were given for the management of diabetes, hypertension or hyperlipidaemia (which was defined as a total cholesterol level ≥ 250 mg/dl or a triglyceride level ≥ 500 mg/dl); any medication use for diabetes and hypertension was classified as a positive criterion for elevated FPG and elevated blood pressure, with regard to the definition of the metabolic syndrome. In addition, during the second year, the total number of new cases treated for diabetes, hypertension or hyperlipidaemia was < 4% (data not shown) of the total number of study subjects.
Logistic regression analysis of the five components showed that significant reductions in SBP, HDL-C and triglycerides, and moderate reductions in DBP, significantly increased the likelihood of metabolic syndrome disappearing after 1 year. A reduction in waist circumference or BMI was, however, not associated with the 1year disappearance of metabolic syndrome, suggesting that short-term weight reduction may do little to change metabolic syndrome status.
In logistic regression modelling, the definition of metabolic syndrome differed according to the use of lipid-lowering medicine as a criterion: model 1 neglected the use of lipid-lowering medicine as a criterion while model 2 included such medicine as a positive criterion for the control of both triglycerides and HDL-C. There was no difference between the two models in terms of the change in metabolic syndrome components and the 1-year disappearance of metabolic syndrome. Nevertheless, only a few subjects used lipid-lowering medicine in this study sample; a larger study is needed to confirm our observation. Other limitations of this study included selection bias, due to the inclusion of subjects being restricted to the community screening project, and the age of this community-based population being different from the general population. Thus, the findings cannot be generalized to the larger population of Taiwan. Additional limitations were the availability of only 2 years of consecutive data, and the fact that measurements of each metabolic syndrome component and BMI were taken only once per year for each subject. Thus, without calculating mean values from data taken over the course of the year it is difficult to make strong conclusions or extrapolate data based on a single annual measurement.
In summary, fluctuations in some of the five components used to define metabolic syndrome were associated with the disappearance of metabolic syndrome after 1 year. Of these components, reduction in BP, HDL-C, and triglycerides but not waist circumference, BMI or FPG, might play an important role in the disappearance of metabolic syndrome. Characteristics of the fluctuations in each component and the subsequent disappearance of metabolic syndrome not only impact the treatment efficacy and outcomes in many studies, they also raise the question of whether metabolic syndrome only temporarily disappears or whether subjects attain remission from metabolic syndrome. Additional evidencebased research is required to explore the long-term disappearance of metabolic syndrome, and questions remain as to how best to define the remission. In addition, further investigations are needed to explore the difference in cardiovascular morbidity and mortality in relation to the disappearance of metabolic syndrome, and a large well-controlled study is needed to determine the role that treatment plays in the disappearance of this syndrome.
